Ovarian cancer is the second most common gynecologic cancer in women and the leading cause of death caused by gynecologic malignancy.
Surgical Staging: Early Ovarian Cancer
Surgery establishes the correct stage of the ovarian cancer. This is important for prognosis and directing appropriate therapy. For example, well-differentiated intracystic ovarian cancer with negative staging biopsies (stage IA, grade I) has a high survival rate (around 95%) and only requires observational follow up.
Understanding the early natural history and patterns of spread of epithelial ovarian cancer forms the basis for a rational system for surgical staging of apparent early ovarian cancer. Clinical observations made during the 1970s formed the basis of staging or restaging laparotomy for early ovarian cancer. 2 A prospective trial of careful surgical staging procedures was performed on patients believed to have stage I or II disease after initial surgery. In this series of 100 patients, 31% of patients were upstaged as a result of additional surgery. Of these, 77% were reclassified as having stage III disease. 3 This information was important in developing the l987 staging system by FIGO (Federation Internationale de Gynecologie et d'Obstetrique) for ovarian cancer (stage IIIA was created by this information; Table 1 ). Histologic grade was an important predictor of occult metastasis: 16% of patients with grade 1 lesions, 34% with grade 2, and 46% with grade 3 were upstaged. Before referral, only 25% of patients had initial surgical incision that was adequate for proper staging.
Since the FIGO report on surgical staging in early ovarian cancer, the importance of bilateral pelvic and para-aortic node dissection has been reported. In one study of 96 patients with gross disease confined to one ovary, and 15% had microscopically positive lymph nodes. 4 Fifty-four patients underwent bilateral node dissections; 19% had positive nodes and 30% of these had contralateral disease. A recent report from the National Cancer Institute's SEER database indicated that only about 10% of American women with apparent early stage ovarian cancer received appropriate surgical staging and recommended postoperative therapy. 5 Women with pelvic masses that may be ovarian cancer should undergo full evaluation and appropriate surgery by a qualified surgeon. Patients with elevated CA 125 or imaging studies suggestive of malignancy have indications for referral. Laparoscopic management of potentially malignant masses is not recommended.
Surgical laparotomy should be performed through a midline or para-median abdominal incision to allow adequate access to the upper abdomen. The ovarian tumor should be removed intact and a frozen section obtained. Patients with ovarian malignancy or at least borderline ovarian cancers and whose tumor is macroscopically confined to the ovaries or the pelvis should undergo meticulous surgical staging (Table 2) . IC: Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings.
Stage II
Stage II ovarian cancer is tumor involving one or both ovaries with pelvic extension and/or implants. 
Stage III
Stage III ovarian cancer is tumor involving one or both ovaries with microscopically confirmed peritoneal implants outside the pelvis. Superficial liver metastasis equals stage III. Tumor is limited to the true pelvis but with histologically verified malignant extension to small bowel or omentum.
IIIA: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor).
IIIB: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension.
IIIC: Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis.
Stage IV
Stage IV ovarian cancer is tumor involving one or both ovaries with distant metastasis. If pleural effusion is present, there must be positive cytologic test results to designate a case to stage IV. Parenchymal liver metastasis equals stage IV.
Source: FIGO Cancer Committee, Gynecol Oncol 1986;25:383-385.
At the time of initial opening of the peritoneum for a suspected ovarian malignancy, any free fluid or ascites should be collected for cytologic evaluation. If no free fluid is present, peritoneal washings should be obtained. After intact removal of the adnexa, if a cancer diagnosis is established, a total abdominal hysterectomy and contralateral salpingo-oophorectomy is performed. In select cases in which fertility preservation is desired, the uterus and opposite adnexa may be preserved. 6 In particular, malignant germ cell neoplasms are unilateral and occur in young women who have not completed childbearing.
A systematic exploration of all intra-abdominal surfaces and viscera should be performed. This includes the peritoneal surfaces of the small and large bowel, including the mesentery, paracolic gutters, under surfaces of both hemidiaphragms, gall bladder, and liver. Any suspicious areas or adhesions should be biopsied. The peritoneum of the pelvic cul-de-sac, bladder peritoneum, and both paracolic gutters should be randomly biopsied. The diaphragm peritoneum should be biopsied or scraped for cytologic evaluation. An infracolic omentectomy should be performed. A pelvic and paraaortic lymph node dissection should be performed, unless there is a positive enlarged node on frozen section.
The final pathologic report of the comprehensive surgical staging provides accurate staging (Table 1) . This provides the basis for most appropriate recommendation for adjuvant treatment. As indicated, patients with a stage IA grade 1 tumor can undergo observation. 7 Other patients with stage I disease who are not on protocols are usually treated with three cycles of taxane and platinum agents. 8 Because of a higher failure rate, stage II disease is managed similarly to more advanced ovarian cancers, with six to eight cycles of taxane and platinum-based chemotherapy.
Restaging surgical procedures should be performed in patients with apparent intracystic and grade 1 tumors that were not adequately staged with the initial surgery. Appendectomies should be performed in patients with mucinous tumors, because 8% of these patients will have involvement of the appendix. 9 Routine appendectomy in early ovarian cancer is controversial and is performed in less than 4% of cases, 10, 11 although the appendix has been reported as the only site of extra-ovarian spread. 12 Grade 3 tumors would be in indication for appendectomy.
Advanced Ovarian Cancer: Cytoreductive Surgery
Advanced ovarian cancer shows a varied spectrum of disease at surgical exploration. Maximal cytoreductive surgery has been the cornerstone of initial surgical management. The theoretical rationales for cytoreductive surgery are: (1) the physiologic benefit of removal of tumor mass or masses and ascites; (2) improved tumor perfusion with chemotherapy; and (3) improved immunologic competence of the patient. Cytoreductive surgery in advanced ovarian cancer is not adequate treatment. Chemotherapy should be started postoperatively. The current standard chemotherapy would be six cycles of paclitaxel and carboplatin. 13 The doses would be paclitaxel 175 mg/m 2 over 3 hours and carboplatin AUC 5.0 to 7.5 every 3 weeks. Data exist that docetaxel 75 mg/m 2 given over one hour could be substituted for paclitaxel 14 ; prospective, randomized chemotherapy research trials integrating other active agents are ongoing. 15 No prospective data are available on cytoreductive surgery, but retrospective evidence supports the advantages of such surgery. The goal of cytoreductive surgery is the removal of the primary cancer and all metastatic disease. This should include removal of the uterus and fallopian tubes as well as the ovaries. If complete resection of tumor is not technically feasible, the goal is to achieve optimal tumor reduction status. Definition of optimal tumor cytoreduction has varied over time. The concept was begun in the 1970s, when researchers noted that patients who underwent surgical cytoreduction of bulky disease to small-volume disease had a longer survival time. 16 Traditionally, this meant cytoreduction of all visible disease to a 2-cm maximum diameter of individual aggregates of disease. 17 Currently, 1-cm tumor diameter individual aggregates is considered optimal cytoreduction 18 ; however, some reports support even smaller diameters. 19, 20 The number of individual aggregates present after a maximal cytoreductive surgery varies widely. For example, one patient may be considered optimally cytoreduced with only two residual tumor implants of 1 cm and another patient with 10 to 12 individual implants. Therefore, the distribution and extent of residual disease are important. 21 In general, median survival doubles from 17 months to 39 months with aggressive surgery rendering the tumor down to optimal residuum. A meta-analysis of 6,885 patients found that maximal cytoreduction was one of the most powerful determinants of survival of patients with advanced ovarian cancer. Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival time. The platinum dose intensity and cumulative dose had no effect on median survival time (that is, a cytoreduction of 75% = median survival of 37 months; cytoreduction of 25% = median survival of 23 months). 22 The literature clearly shows that gynecologic oncologists are the most qualified and capable surgeons for attempting maximal cytoreduction surgery for ovarian cancer. To optimize the surgical results requires skills, experience, and judgment. The range of surgery for pelvic resection of uterus, tubes, and ovarian cancer may require modified or radical hysterectomy and even a posterior exenteration. In addition to omentectomy and pelvic and para-aortic node dissection, bowel resection or splenectomy may be indicated.
Ovarian cancer generally does not penetrate into the retroperitoneal space. Therefore, use of retroperitoneal surgical approach enables en bloc resection of pelvic disease. The ureters need to be identified and protected from injury. They are often distorted by tumor geometry and can be adherent to pelvic tumors.
The omentum in advanced ovarian cancer may be just studded with small metastasis or entirely replaced, forming an omental cake. One approach to removing the omentum is to dissect the omentum off the transverse colon in the avascular plane. Another approach is to open the lesser sac off the greater curvature of the stomach. If it is necessary to ligate the short gastric arteries, a nasogastric tube should be used postoperatively because of delayed gastric emptying.
The hilum of the spleen is often a site of extension of bulky omental ovarian metastasis. Splenectomy may be necessary to accomplish optimal cytoreduction or to control bleeding caused by traction on the splenic capsule. 23 During splenectomy, care must be exercised to not damage the tail of the pancreas, which can lead to leak or fistulae. If the spleen is removed, immunization against Streptococcus pneumoniae, meningococcus, and Haemophilus influenzae should be performed postoperatively because these patients will be at higher risk for infection secondary to encapsulated organisms.
Retroperitoneal lymph nodes contain metastatic disease in up to 70% of patients with advanced ovarian cancer. In patents with isolated enlarged pelvic or para-aortic nodes, removal is mandatory in an optimal cytoreductive surgical effort. However, the role of systematic lymphadenectomy in patients with no palpably enlarged lymph nodes with advanced metastatic disease is unclear.
Advanced ovarian cancer often involves both the large and small bowel. The literature confirms that optimal cytoreduction to less than 1 cm of residual disease results in an improved survival of patients undergoing bowel resection at the time of primary surgery. 24 Although ovarian cancer typically does not invade into the muscularis and mucosa of the intestine, clinically, metastatic implants that may exist in the bowel mesentery or serosa can cause obstruction or impending obstruction, and resection is indicated. In addition to the rectosigmoid, the most frequent sites of resection are the terminal ileum, cecum, and transverse colon. Resection of more than one segment may be necessary. Appendectomy should be performed if gross involvement with tumor is present or if the histology is a mucinous tumor.
Other ancillary procedures or techniques have been employed. These include diaphragm stripping and the use of argon beam coagulation or Cavitron ultrasonic surgical aspiration (CUSA). [25] [26] [27] [28] However, the efficacy of these procedures of improving outcome is unproven.
Ovarian Cancer: Secondary Surgery
Secondary surgery for epithelial ovarian cancer may be defined as surgery undertaken some time after the completion of primary staging surgery or cytoreductive surgery. This includes second-look laparotomy (SLL), secondary cytoreductive surgery, interval cytoreductive surgery, surgery for recurrent disease, and surgery for intestinal obstruction.
Second Look Laparotomy
SLL was incorporated into ovarian cancer management in the 1970s, when the appropriate duration of chemotherapy was unknown. At that time, the risks of iatrogenic malignancies were recognized with prolonged exposure to alkylating agents. 29, 30 Duration of treatment was directed by response as documented in a secondary surgical procedure. With the advent of platinum and paclitaxel-based primary therapy, concerns related to prolonged alkylating agent therapy have been overcome, and the role of SLL in directing treatment is diminishing.
The routine use of SLL in patients with ovarian carcinoma is controversial. Although clinicians may interpret the optimal purpose and timing of SLL with some variability, its definition as a comprehensive surgical staging procedure in a patient clinically free of disease (no evidence on physical examination, negative imaging studies, and normal tumor markers) is less ambiguous. As a noncurative procedure, its diagnostic value may be limited by random sampling techniques, and as a major surgical procedure, the potential exists for serious complications and impact on the patient's quality of life. 31 In addition, from a macroeconomic perspective, the costs associated with SLL are not inconsequential.
Despite these risks, SLL is the gold standard for identifying residual disease after standard first-line platinum-based chemotherapy. To benefit patients, SLL must be highly predictive of the presence or absence of disease and result in therapeutic decisions that improve survival.
In early stage disease, patients who have undergone appropriate ovarian cancer surgery and chemotherapy are not recommended for second-look surgery because of the low yield of positive findings indicating persistent disease. Two series reported in the literature regarding SLL in early stage ovarian cancers showed positive findings in only 5% and 12% of the surgeries, respectively. 7, 32 However, in advanced ovarian cancer, more than 50% of patients will have a positive second-look evaluation despite negative clinical evidence of disease. Additionally, the prognostic value is questionable because even among those with a negative SLL, the risk of recurrence is greater than 50%. In reports of two European multicenter randomized trials of SLL, neither study showed any survival benefit. 33, 34 These studies have been criticized because of methodologic flaws and the chemotherapy used.
Gynecologic Oncology Group (GOG) Protocol 158 was a randomized trial in patients with optimally resected stage III ovarian cancer whose primary objective was designed as a non-inferiority study to compare the efficacy and toxicity of carboplatin plus paclitaxel (arm II) with cisplatin plus paclitaxel (arm 1). Seven hundred ninety-two eligible patients were enrolled on the study. Prognostic factors were similar in the two treatment groups. Median PFS and overall survival was 19.4 and 48.7 months, respectively, for arm I compared with 20.7 and 57.4 months, respectively, for arm II. The relative risk (RR) of progression for the carboplatin plus paclitaxel group was 0.88 with a 95% confidence interval (CI) of 0.75 to 1.03, and the RR of death was 0.84 with a 95% CI of 0.70 to 1.02. 13 SLL was not required but was used to assess response to treatment, which reflects the uncertainty of whether a second-look procedure enhances the overall treatment of patients with ovarian cancer. Patients were informed regarding the arguable value of second-look procedures before chemotherapy randomization. If they elected to undergo the procedure, they were registered with the GOG Statistical and Data Center (SDC). The choice was used as a stratification factor to insure balance of treatment assignment within the SLL and no SLL groups. In the absence of a randomized trial, GOG 158 provided a large prospective comparison of survival in patients who underwent SLL compared with those who were followed up clinically after completion of initial chemotherapy.
A nonrandomized, prospective comparison of progression-free survival (PFS) and survival in patients who underwent SLL versus patients who were followed up clinically was performed after completion of initial chemotherapy for optimally resected stage III ovarian cancer. Before chemotherapy randomization, patients participating in GOG Protocol 158 were informed of the controversies regarding SLL before choosing whether or not they would undergo the procedure (disease at SLL was not a study endpoint). Any chemotherapy initiated after finding disease at SLL or clinical recurrence was not standardized but physician-directed. The intent-to-treat approach customarily used in randomized clinical trials was replaced by explanatory analysis.
Three hundred ninety-three patients selected SLL and 399 selected no SLL. Median age of patients in the SLL group was 54 compared with 59 in the no SLL group, and patients selecting SLL were more likely than those in the no SLL group to have gross residual disease at initial surgery (69% vs. 60%, respectively), implying a need for adjusted analysis. The adjusted relative risk was .089 (95% CI, 0.75-1.07) and the difference in median PFS was 1.0 month (SLL 23.9 vs. no SLL 22.9 months). No difference in survival was seen between the two groups. 35 SLL combined with physician-directed secondline therapy for patients with positive SLL does not appear to substantially improve PFS or improve survival to any degree. SLL remains the gold standard for determining the presence or absence of disease. Ethically, for patient autonomy, SLL should be discussed because patients with a negative SLL result have a better prognosis. SLL can be used in patients with disease distribution that would make them candidates for consolidation treatment such as whole abdomen radiation. In summary, however, SLL has limited application with current chemotherapy agents and should be reserved for research purposes.
Secondary and Interval Cytoreductive Surgery
Interval cytoreductive surgery after neoadjuvant chemotherapy has been used in a number of clinical contexts. The most common clinical situation is for patients with suboptimal cytoreduction; after several cycles of chemotherapy, an attempt at further cytoreduction is made. The second most common context is for patients who are medically compromised and not candidates for initial radical cytoreduction because of risk of incurring severe morbidity. After six cycles of platinum-based chemotherapy, some practitioners will offer patients debulking surgery if they have had a good response with reduction in total bulk of disease. The third context is for patients who are electively treated with neoadjuvant chemotherapy and interval cytoreduction as primary therapy. These last two clinical situations are for patients who have had diagnosis by cytology or some type of biopsy.
Two large prospective randomized trials looking at outcomes in interval cytoreduction have been reported. An EORTC study of 319 patients showed a median survival time of 26 months for patients who underwent interval cytoreduction and 20 months for those who did not (P = .04). 36 This study involved patients with suboptimal initial surgery and three cycles of cisplatin and cyclophosphamide without progression before randomization. The GOG reported similar approach in 550 patients, but used three cycles of paclitaxel and cisplatin chemotherapy before surgery versus continued chemotherapy. The median survival time was 32 months for the interval group and 33 months for those receiving chemotherapy. 37 Secondary cytoreduction surgery at the time of recurrence requires good judgment and experience. Patients who had complete or optimal resection at the primary surgery or a disease-free interval of more than a year are most likely to benefit. Patients should show clinical and radiologic evidence that the recurrent disease is resectable.
Surgery for Intestinal Disease
Intestinal obstruction is a common problem in ovarian cancer patients during the course of the disease. This clinical dilemma requires thoughtful evaluation and management before surgical intervention. Obstruction may be related to a mechanical blockage or to carcinomatosis. Initial management should be hydration and correction of any electrolyte abnormalities. Thorough imaging studies need to be performed to document type and number of obstructions and guide the decision to perform an exploratory procedure. Patients with very short life expectancy should not undergo exploration. If exploratory surgery is deemed appropriate, the range of procedures would include resection with anastomosis, colostomy, ileostomy, or jejunostomy. Gastrotomy tube placement may be indicated for palliation in some circumstances. Recently, intestinal stents have been placed using endoscopic procedures. Clinical experience, good judgment, and excellent surgical skills are critical to maximize outcome in this difficult clinical problem.
Conclusions
Surgery plays a vital role in the management of ovarian cancer. The goals include diagnosis, proper staging, therapeutic cytoreduction, and palliation. The rationale and guidelines have been outlined. To maximize outcomes for women with ovarian cancer, clinical experience, judgment, and a varied set of surgical skills are necessary.
